Kirsten Katrine Lindegaard has a diverse work experience. Kirsten Katrine is currently serving as the Chief Executive Officer at OsteoStrong since October 2022. Prior to this, they were the Managing Director Denmark at OsteoStrong from September 2020 to October 2022. Kirsten Katrine is also a Partner at X3 Bar since August 2020 and a Co-founder at OsteoStrong Denmark since October 2018.
In addition, Kirsten has worked at various other organizations. These include being a Partner at Theos Coffee Shop from August 2020 to October 2021. Previously, they worked at LEO Pharma as a Global Senior Medical Advisor (tralokinumab) from June 2019 to August 2020 and as a Global Medical Advisor (tralokinumab) from October 2016 to June 2019.
Kirsten's earlier roles include working at Zealand Pharma as a Scientist, PhD. Kirsten Katrine was involved in project development for setting up an immunoassay platform within early drug discovery, focusing on inflammation-related biomarkers. Kirsten Katrine also served as an Industrial Ph.D. student and Research Assistant during their time at Zealand Pharma.
Before joining Zealand Pharma, Kirsten worked as a Research Assistant at the National Veterinary Institute. Kirsten Katrine gained knowledge in the field of inflammation and was involved in the development and optimization of a non-established RNA extraction procedure on coagulated blood.
Overall, Kirsten Katrine Lindegaard has a strong background in various fields, including executive leadership, management, partnership, and scientific research.
Kirsten Katrine Lindegaard has a diverse educational background. Kirsten Katrine first attended the University of Copenhagen from 2001 to 2004, where they obtained a Bachelor of Science degree in Biology. Kirsten Katrine then pursued a Bachelor of Science degree in Life Science and Biotechnology at the Technical University of Denmark from 2005 to 2007. Following this, they continued their studies at the same institution and earned a Cand. polyt degree in Biotechnology from 2007 to 2010. Kirsten further expanded their knowledge in the field of BioBusiness and Innovation by attending the BioBusiness & Innovation Program at the Copenhagen Business School from 2010 to 2011. Finally, they completed their academic journey by obtaining a Doctor of Philosophy degree from the Technical University of Denmark between 2011 and 2015. The specific field of study for their PhD is not provided.
Sign up to view 8 direct reports
Get started